On Tuesday, Intra-Cellular Therapies Inc (NASDAQ: ITCI) was -0.03% drop from the session before settling in for the closing price of $131.28. A 52-week range for ITCI has been $63.30 – $131.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 7627.06%. When this article was written, the company’s average yearly earnings per share was at 186.24%. With a float of $98.98 million, this company’s outstanding shares have now reached $106.24 million.
Let’s determine the extent of company efficiency that accounts for 860 employees. In terms of profitability, gross margin is 91.63%, operating margin of -17.15%, and the pretax margin is -10.9%.
Intra-Cellular Therapies Inc (ITCI) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Intra-Cellular Therapies Inc stocks. The insider ownership of Intra-Cellular Therapies Inc is 6.91%, while institutional ownership is 82.90%. The most recent insider transaction that took place on Dec 04 ’24, was worth 4,375,659. In this transaction Chairman and CEO of this company sold 51,000 shares at a rate of $85.80, taking the stock ownership to the 1,070,329 shares. Before that another transaction happened on Dec 05 ’24, when Company’s Chairman and CEO sold 51,697 for $84.08, making the entire transaction worth $4,346,842. This insider now owns 1,070,329 shares in total.
Intra-Cellular Therapies Inc (ITCI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 186.24% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
You can see what Intra-Cellular Therapies Inc (ITCI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.72, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach 4.06 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Looking closely at Intra-Cellular Therapies Inc (NASDAQ: ITCI), its last 5-days average volume was 2.88 million, which is a drop from its year-to-date volume of 3.91 million. As of the previous 9 days, the stock’s Stochastic %D was 73.75%. Additionally, its Average True Range was 1.02.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 99.80%, which indicates a significant increase from 96.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 9.87% in the past 14 days, which was lower than the 57.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $114.81, while its 200-day Moving Average is $85.91. However, in the short run, Intra-Cellular Therapies Inc’s stock first resistance to watch stands at $131.33. Second resistance stands at $131.42. The third major resistance level sits at $131.48. If the price goes on to break the first support level at $131.18, it is likely to go to the next support level at $131.12. Now, if the price goes above the second support level, the third support stands at $131.03.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
There are 106,328K outstanding shares of the company, which has a market capitalization of 13.95 billion. As of now, sales total 680,850 K while income totals -74,680 K. Its latest quarter income was 199,220 K while its last quarter net income were -16,890 K.
